Albireo Pharma, Inc. (ALBO): Price and Financial Metrics
ALBO Price/Volume Stats
| Current price | $44.15 | 52-week high | $45.23 |
| Prev. close | $44.25 | 52-week low | $16.02 |
| Day low | $43.99 | Volume | 1,241,200 |
| Day high | $44.90 | Avg. volume | 704,539 |
| 50-day MA | $37.97 | Dividend yield | N/A |
| 200-day MA | $25.15 | Market Cap | 913.95M |
ALBO Stock Price Chart Interactive Chart >
Albireo Pharma, Inc. (ALBO) Company Bio
Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders. The company is based in Boston, Massachusetts.
Latest ALBO News From Around the Web
Below are the latest news stories about ALBIREO PHARMA INC that investors may wish to consider to help them evaluate ALBO as an investment opportunity.
Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: Should You Buy?Mirum Pharmaceuticals, Inc. (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Is Albireo Pharma (ALBO) Stock Outpacing Its Medical Peers This Year?Here is how Albireo Pharma (ALBO) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year. |
FDA Grants June 15, 2023 PDUFA Date to Albireo for Bylvay® in Alagille SyndromeBylvay (odevixibat) granted Priority Review by U.S. FDAASSERT study demonstrated efficacy of Bylvay in pruritus, bile acids and sleep with a low drug-related diarrhea rate in Alagille patientsApproval in second indication would more than double Bylvay market opportunity BOSTON, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced that the U.S. Food and Drug |
Why These Two Biotech Stocks Blasted Higher This WeekTwo somewhat under-the-radar biotech companies saw their share prices soar this week after agreeing to be acquired. CinCor Pharma (NASDAQ: CINC) is being bought out by deep-pocketed pharmaceutical company AstraZeneca, while Albireo Pharma (NASDAQ: ALBO) is set to be owned by France-based peer Ipsen. Both of these deals are very lucrative, to the point where CinCor's stock rocketed 146% over the course of the week, and Albireo shot 92% skyward, according to data compiled by S&P Global Market Intelligence. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayWe're starting off the week with a look at the biggest pre-market stock movers traders need to know about on Monday morning! |
ALBO Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | 92.46% |
| 3-year | 16.95% |
| 5-year | 66.92% |
| YTD | 104.30% |
| 2022 | -7.21% |
| 2021 | -37.91% |
| 2020 | 47.56% |
| 2019 | 3.63% |
| 2018 | -4.18% |
Continue Researching ALBO
Want to do more research on Albireo Pharma Inc's stock and its price? Try the links below:Albireo Pharma Inc (ALBO) Stock Price | Nasdaq
Albireo Pharma Inc (ALBO) Stock Quote, History and News - Yahoo Finance
Albireo Pharma Inc (ALBO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...